6:01 AM
 | 
Jan 03, 2019
 |  BC Innovations  |  Translation in Brief

Neo opportunities in glioblastoma

BioNTech, Immatics lay groundwork for personalized glioblastoma immunotherapy

Phase I results from a consortium led by BioNTech AG and Immatics Biotechnologies GmbH convinced both companies that personalized immunotherapies can turn on T cell activity in glioblastoma, an immunologically "cold" cancer.

The study is one of the first two reports of neoantigen vaccines in glioblastoma in the clinic. In the same issue of Nature, a Dana-Farber Cancer Institute group showed similar results with a different vaccination strategy.

While the vaccines in both studies produced immune responses but not clinical benefit, BioNTech and Immatics think adapting the approach to their platforms could boost antitumor responses.

BioNTech co-founder and CEO Ugur Sahin...

Read the full 495 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >